Watch the Pulsar-18 T3 in action to treat multiple SFA stenoses.

Case courtesy of Drs. Luis Mariano Palena and Marco Manzi.

Clinically Proven Even in Complex Lesions2

Strong results with no significant difference in outcomes between calcified and noncalcified lesions
24 - m FTLR 4EVER3
Positive results even for long and occluded lesions in a high risk population
12 - m FTLR TASC D4
All-comers registry shows sustained results in a real world population
24 - m FTLR BIOFLEX PEACE5 (stent only)

What is COF and why does it matter?

Chronic outward force (COF) is the force exerted on the vessel wall by a self-expanding stent to achieve its present diameter.6 Thinner struts, which have lower COF*, result in a lower risk of restenosis, reduced vessel injury and inflammation and faster endothelialization.7,8,9

Thinner struts for lower COF10

Achieve less mean restenosis with
low-COF Pulsar-18 T311

*as demonstrated in pre-clinical studies

Physician Testimonials

How did you find using Pulsar-18 T3 the first time?
How does Pulsar-18 T3 meet your treatment objectives?
Why is 4-F treatment important for patients?

Easy to use, ergonomically designed.

The first tri-axial, 4F thin-strut stent system for the treatment of lower limb PAD.1

Contact us

PLEASE FILL IN THE FORM BELOW TO ALLOW US TO CONTACT YOU.
THANK YOU FOR YOUR INTEREST
A contact from a local BIOTRONIK team will be in touch soon about your inquiry.
  • 1. PAD – Peripheral Artery Disease;
  • 2. Bosiers M. 4EVER 24 month results: long-term results of 4F Pulsar stent in femoropopliteal lesions. Presented at: CIRSE 2013; Barcelona, Spain:
  • 3. Deloose K. 4EVER 24m: Long-term results of 4F Pulsar stents in femoropopliteal lesions. Presented at: LINC; Jan 29, 2014; Leipzig, Germany:
  • 4. Lichtenberg M. Superficial Femoral Artery TASC D registry: 12-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013 ; 54(4):433-9;
  • 5. Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions - the BIOFLEX PEACE All-Comers Registry.Vasa (2019), 1-9. doi_10.10240301- 1526a000785;
  • 6. Freeman JW, et al. A link between stent radial forces and vascular wall remodeling: the discovery of an optimal stent radial force for minimal vessel restenosis. Connect Tissue Res. 2010 Aug; 54(4): 314-26;
  • 7. Zhao HQ Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc. Interv. Radiol. 2009; 32(4); 720-6;
  • 8. Koskinas C. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. JACC 2012 10;59(15):1337-49;
  • 9. Koppara T. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv.2015 8(6):e002427.
  • 10. BIOTRONIK data on file. 6.0 mm diameters. Supera stent not possible to test due to its design and applied test method;
  • 11. Funovics M. Differences in clinical outcomes of low COF stent vs high COF stent proven in clinical practice. Presented at: CIRSE, Sep 8, 2019; Barcelona, Spain;
  • Pulsar is a trademark or registered trademark of the BIOTRONIK Group of Companies.